Related Experiment Video
Updated: Feb 15, 2026

BtM, a Low-cost Open-source Datalogger to Estimate the Water Content of Nonvascular Cryptogams
Published on: March 25, 2019
Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Alejandra Maciel1, Ali Cullors1, Andrew A Lukowiak1
1AltheaDx, San Diego, CA, USA.
Abstract:
The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic efficacy and improve symptoms in patients diagnosed with depression, but limited data are available on the cost savings of pharmacogenetic-guided interventions outside of psychiatric clinical specialties. Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings. Assuming a test cost of USD$2,000 for pharmacogenetic testing, the model predicts a savings of USD$3,962 annually per patient with pharmacogenetic-guided medication management.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Pharmacogenetics and Pharmacogenomics: Overview
Long-term Depression
Mitral Stenosis II: Clinical features and Diagnostic Tests

